Literature DB >> 1532236

Host factors associated with HIV-related oral candidiasis. A review.

G M McCarthy1.   

Abstract

Human immunodeficiency virus (HIV)-related oral candidiasis affects approximately one third of HIV-seropositive patients and more than 90% of patients with AIDS. It is necessary to identify patients who have a greater risk of candidiasis developing, so that interventions can be designed to reduce the frequency. This is particularly important because there is evidence that Candida species are immunosuppressive and therefore candidiasis may adversely affect the prognosis of patients with HIV. Susceptibility to HIV-related oral candidiasis is associated with xerostomia, severity of disease, depression of cell-mediated immunity, and older age (greater than 35 years). The frequency of HIV-related oral candidiasis is notably increased when the CD4 lymphocyte count falls to less than 300 cells/mm3. Xerostomia appears to be a better predictor of HIV-related oral candidiasis than CD4 count and should be prevented (e.g., by avoiding xerogenic drugs) and treated, when necessary, to minimize the risk of oral candidiasis.

Entities:  

Mesh:

Year:  1992        PMID: 1532236     DOI: 10.1016/0030-4220(92)90192-s

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  18 in total

1.  Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice.

Authors:  R D Wagner; C Pierson; T Warner; M Dohnalek; J Farmer; L Roberts; M Hilty; E Balish
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 2.  Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.

Authors:  Peter A Reichart
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

3.  T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis.

Authors:  C S Farah; S Elahi; G Pang; T Gotjamanos; G J Seymour; R L Clancy; R B Ashman
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Enhanced clearance of Candida albicans from the oral cavities of mice following oral administration of Lactobacillus acidophilus.

Authors:  S Elahi; G Pang; R Ashman; R Clancy
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Utilization of dental care services among low-income HIV-positive persons receiving primary care in South Florida.

Authors:  Margaret Pereyra; Lisa R Metsch; Scott Tomar; Eduardo Valverde; Yves Jeanty; Shari Messinger; Henry Boza
Journal:  AIDS Care       Date:  2011-01

6.  Increasing access to oral health care for people living with HIV/AIDS in the U.S.: baseline evaluation results of the Innovations in Oral Health Care Initiative.

Authors:  Jane E Fox; Carol R Tobias; Sara S Bachman; David A Reznik; Serena Rajabiun; Niko Verdecias
Journal:  Public Health Rep       Date:  2012-05       Impact factor: 2.792

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility.

Authors:  Natalya U Makarova; V V Pokrowsky; A V Kravchenko; L V Serebrovskaya; Michael J James; Michael M McNeil; Brent A Lasker; David W Warnock; Errol Reiss
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Barriers and facilitators to dental care among HIV-Infected adults.

Authors:  Carrigan Parish; Karolynn Siegel; Margaret Pereyra; Terri Liguori; Lisa Metsch
Journal:  Spec Care Dentist       Date:  2015-09-04

Review 10.  T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design.

Authors:  L Romani; E Cenci; A Menacci; F Bistoni; P Puccetti
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.